chr11-108272808-C-A
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 0P and 1B. BP4
The NM_000051.4(ATM):c.3240C>A(p.Asp1080Glu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000558 in 1,614,068 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000051.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -1 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATM | NM_000051.4 | c.3240C>A | p.Asp1080Glu | missense_variant | Exon 22 of 63 | ENST00000675843.1 | NP_000042.3 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152170Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000239 AC: 6AN: 251264Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135772
GnomAD4 exome AF: 0.00000479 AC: 7AN: 1461780Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 727198
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152288Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74458
ClinVar
Submissions by phenotype
Ataxia-telangiectasia syndrome Uncertain:2Benign:1
- -
- -
- -
Hereditary cancer-predisposing syndrome Uncertain:2
This missense variant replaces aspartic acid with glutamic acid at codon 1080 of the ATM protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 26976419). This variant has been identified in 6/251264 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.D1080E variant (also known as c.3240C>A), located in coding exon 21 of the ATM gene, results from a C to A substitution at nucleotide position 3240. The aspartic acid at codon 1080 is replaced by glutamic acid, an amino acid with highly similar properties. This alteration has been reported in the germline of a male diagnosed with acute mega-karyoblastic leukemia and synchronous mediastinal germ cell tumor of common clonal origin at age 17 (Oshrine BR et al. Cancer Genet 2014 Apr; 207(4):153-9). This alteration has also been reported in a cohort of 488 patients with stages I to III breast cancer who were tested with a 25-gene panel test (Tung N et al. J. Clin. Oncol., 2016 May;34:1460-8). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
not specified Uncertain:1
Variant summary: ATM c.3240C>A (p.Asp1080Glu) results in a conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 251264 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.3240C>A has been reported in the literature as a VUS in an individual with breast cancer (example, Tung_2016), a study cohort of individuals undergoing WES for neurodevelopmental disorders without a cancer diagnosis (example, Kraemer_2019), a male with acute megakaryoblastic leukemia and mediastinal germ cell tumor (example, Oshrine_2014). These report(s) do not provide unequivocal conclusions about association of the variant with Breast Cancer/Ataxia Telangiectasia. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Six clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
not provided Uncertain:1
This variant is denoted ATM c.3240C>A at the cDNA level, p.Asp1080Glu (D1080E) at the protein level, and results in the change of an Aspartic Acid to a Glutamic Acid (GAC>GAA). This variant has been observed in at least one patient with breast cancer as well as in an individual with concurrent acute megakaryoblastic leukemia and a mediastinal germ cell tumor, and was absent from 400 control samples (Oshrine 2014, Tung 2016). ATM Asp1080Glu was observed at an allele frequency of 0.026% (4/15,300) in individuals of African ancestry in large population cohorts (Lek 2016). This variant is located within the region of interaction with beta-adaptin (Tavtigian 2009). In-silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. Based on currently available evidence, it is unclear whether ATM Asp1080Glu is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. -
Familial cancer of breast Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at